Up-front rituximab-based chemotherapy has improved outcomes in non-Hodgkin lymphoma (NHL); refractory or relapsed NHL still accounts for approximately 18,000 deaths in the United States. Autologous hematopoietic stem cell transplantation (SCT) can improve survival in primary refractory or relapsed aggressive NHL and mantle cell lymphoma and in relapsed follicular or peripheral T-cell lymphoma. Autologous SCT as a consolidation therapy after first complete or partial remission in high-risk aggressive NHL, mantle cell lymphoma, and peripheral T-cell lymphoma may improve progression-free survival. Allogeneic SCT offers a lower relapse rate but a higher nonrelapse mortality resulting in overall survival similar to autologous SCT.
Keywords: Allogeneic hematopoietic stem cell transplantation; Autologous hematopoietic stem cell transplantation; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Non-Hodgkin lymphoma; Peripheral T-cell lymphoma.
Copyright © 2014 Elsevier Inc. All rights reserved.